Our Clinically-Validated Masking Technology and Approach

We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer.

Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.

• Our integrated biology and protein engineering approach enables us to design and develop highly potent, masked biologics that remain masked (or inactive) until they reach the tumor microenvironment, where they are unmasked (or activated) by tumor-specific matrix metalloproteases (MMPs) and other tumor-specific proteases.
• By leveraging tumor-selective activation, Xilio’s molecules are designed to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.

We are currently advancing multiple programs in preclinical and clinical development for masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie and Gilead.